Video Interview: Grünenthal Reveals Plans To Maintain Robust Growth Following Strong 2015
This article was originally published in Scrip
While other pharma majors have struggled against a number of headwinds, Grünenthal GmbH saw a solid year of growth in 2015 with anticipated revenues of some €1.2bn. Speaking to Informa Pharma Insight's global director of content Mike Ward at the recent Biotech Showcase, Grünenthal's CSO, Dr. Klaus Langner, explains what underpinned this performance as well as discussing the company's plans to expand beyond its core strength in pain management to niche therapeutic fields. Plans include increasing investment in R&D, establishing new partnerships and licensing agreements to bolster the pipeline and existing product portfolios to access assets identified by a four-person innovative medicines unit.